Bio: Robert Landsiedel is Vice President of special toxicology at BASF SE in Ludwigshafen am Rhein, Germany. He previously worked for BASF in development, regulatory and management roles in the USA and in Japan. He is an associate professor (Privatdozent) at the Free University of Berlin and has further teaching positions in Leipzig and Landau. His team at BASF is performing more than 500 regulatory toxicological studies per year under GLP, GIVIMP and ISO17020 as well as screenings for product development. In addition, they are developing new toxicological methods and testing strategies. They have received more than 20 external grants (German BMBF- and EU-funded) and their work has been recognized by several awards including the German Research Award for the development of alternative methods, German GT-Toxicology Award, the Responsible Care Award of the European Chemical Industry Council (Cefic) and the Herbert E. Stokinger Awards of the American Conference of Governmental Industrial Hygienists (ACGIH). Robert received a doctorate degree in chemistry (Dr. rer. nat.), a postgraduate degree in toxicology, and a habilitation in pharmacology and toxicology. He is a Diplomate of the American Board of Toxicology (DABT) and a Fellow of American Academy of Toxicological Sciences (FATS). He was appointed member of the European Commission’s Scientific Committee for Occupational Exposure Levels (SCOEL) where he chaired the methodology working group until the Committee’s decommissioning in 2019. Currently he is the chair for human toxicology of German National Hub within the "Partnership for the Assessment of Risk from Chemicals (PARC), the chairman of the German Toxicology Society (GT) and President of the German Society for experimental and clinical Pharmacology and Toxicology (DGPT).

Abstract: To enhance confidence in in vitro New Approach Methodologies (NAMs), it is essential that test method development and application adhere to established standards, ensuring the generation of rigorous and reproducible data. The OECD Guidance Document No. 286 on Good In Vitro Method Practices (GIVIMP), adopted in 2018, provides a comprehensive framework of technical and quality practices. This guidance is intended for method developers, validation bodies, and end users, and is independent of other quality assurance systems such as Good Laboratory Practice (GLP). GIVIMP offering specific recommendations for in vitro work not covered by other quality standards. Unlike GLP, GIVIMP is focusing on in vitro methods and offers a targeted quality assurance with manageable resources. Its implementation helps prevent unnecessary failures in both academic and commercial settings. Consequently, GIVIMP not only ensures the production of reliable data by NAMs but also enhances the efficiency and effectiveness of method development in commercial and academic labs. GIVIMP promotes standardization, validation, quality control, thorough documentation, ethical considerations, relevance to human health, and interdisciplinary collaboration.

Abstract: To enhance confidence in in vitro New Approach Methodologies (NAMs), it is essential that test method development and application adhere to established standards, ensuring the generation of rigorous and reproducible data. The OECD Guidance Document No. 286 on Good In Vitro Method Practices (GIVIMP), adopted in 2018, provides a comprehensive framework of technical and quality practices. This guidance is intended for method developers, validation bodies, and end users, and is independent of other quality assurance systems such as Good Laboratory Practice (GLP). GIVIMP offering specific recommendations for in vitro work not covered by other quality standards. Unlike GLP, GIVIMP is focusing on in vitro methods and offers a targeted quality assurance with manageable resources. Its implementation helps prevent unnecessary failures in both academic and commercial settings. Consequently, GIVIMP not only ensures the production of reliable data by NAMs but also enhances the efficiency and effectiveness of method development in commercial and academic labs. GIVIMP promotes standardization, validation, quality control, thorough documentation, ethical considerations, relevance to human health, and interdisciplinary collaboration.